Kelly is the Project Director of Clinical Development Operations at Gate Neurosciences. She brings nearly 20 years of clinical development and operations experience, overseeing clinical trials for multiple novel CNS programs from start up through NDA submission. Kelly joins Gate most recently from Acadia Pharmaceuticals Inc., where she led clinical studies in schizophrenia, both adjunctive treatment and negative symptoms, and rare neurological diseases including Rett syndrome and Prader Willi syndrome. While at Acadia, Kelly and her team successfully executed and delivered the trofinetide oral solution (DAYBUE^TM) approval for adults and children with Rett syndrome, the first FDA approved drug for this rare disease.

Prior to joining Acadia, Kelly spent several years working in the biomedical imaging and CRO sectors of clinical development. Her areas offocus included musculoskeletal outcomes in trials in the areas of obesity, diabetes, rheumatoid arthritis and Morquio A Syndrome.

Kelly received her a BA from Seton Hall University.